Metabolic syndrome, endocrine disruptors and prostate cancer associations: Biochemical and pathophysiological evidences

Vincenzo Quagliariello, Sabrina Rossetti, Carla Cavaliere, Rossella Di Palo, Elvira Lamantia, Luigi Castaldo, Flavia Nocerino, Gianluca Ametrano, Francesca Cappuccio, Gabriella Malzone, Micaela Montanari, Daniela Vanacore, Francesco Jacopo Romano, Raffaele Piscitelli, Gelsomina Iovane, Maria Filomena Pepe, Massimiliano Berretta, Carmine D'Aniello, Sisto Perdonà, Paolo MutoGerardo Botti, Gennaro Ciliberto, Bianca Maria Veneziani, Francesco De Falco, Piera Maiolino, Michele Caraglia, Maurizio Montella, Rosario Vincenzo Iaffaioli, Gaetano Facchini

Research output: Contribution to journalReview article

Abstract

This review summarizes the main pathophysiological basis of the relationship between metabolic syndrome, endocrine disruptor exposure and prostate cancer that is the most common cancer among men in industrialized countries. Metabolic syndrome is a cluster of metabolic and hormonal factors having a central role in the initiation and recurrence of many western chronic diseases including hormonal-related cancers and it is considered as the world's leading health problem in the coming years. Many biological factors correlate metabolic syndrome to prostate cancer and this review is aimed to focus, principally, on growth factors, cytokines, adipokines, central obesity, endocrine abnormalities and exposure to specific endocrine disruptors, a cluster of chemicals, to which we are daily exposed, with a hormone-like structure influencing oncogenes, tumor suppressors and proteins with a key role in metabolism, cell survival and chemo-resistance of prostate cancer cells. Finally, this review will analyze, from a molecular point of view, how specific foods could reduce the relative risk of incidence and recurrence of prostate cancer or inhibit the biological effects of endocrine disruptors on prostate cancer cells. On the basis of these considerations, prostate cancer remains a great health problem in terms of incidence and prevalence and interventional studies based on the treatment of metabolic syndrome in cancer patients, minimizing exposure to endocrine disruptors, could be a key point in the overall management of this disease.

Original languageEnglish
Pages (from-to)30606-30616
Number of pages11
JournalOncotarget
Volume8
Issue number18
DOIs
Publication statusPublished - 2017

Keywords

  • Cancer
  • Endocrine disruptors
  • Metabolic syndrome
  • Nutrition
  • Prostate

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Metabolic syndrome, endocrine disruptors and prostate cancer associations: Biochemical and pathophysiological evidences'. Together they form a unique fingerprint.

  • Cite this

    Quagliariello, V., Rossetti, S., Cavaliere, C., Di Palo, R., Lamantia, E., Castaldo, L., Nocerino, F., Ametrano, G., Cappuccio, F., Malzone, G., Montanari, M., Vanacore, D., Romano, F. J., Piscitelli, R., Iovane, G., Pepe, M. F., Berretta, M., D'Aniello, C., Perdonà, S., ... Facchini, G. (2017). Metabolic syndrome, endocrine disruptors and prostate cancer associations: Biochemical and pathophysiological evidences. Oncotarget, 8(18), 30606-30616. https://doi.org/10.18632/oncotarget.16725